Recent advancements in cancer treatments have provided new hope for patients, with significant progress showcased in the biopharmaceutical industry. The interim results of ArriVent BioPharma, Inc.'s Phase 1b FURTHER trial for their drug firmonertinib have been particularly promising. This trial
In a significant advancement for non-small cell lung cancer (NSCLC) treatment, Akeso and Summit Therapeutics have revealed astounding results from their phase 3 HARMONi-2 trial. Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated remarkable efficacy against Merck’s Keytruda, positioning
In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is
The landscape of biopharmaceutical research and development (R&D) has seen a remarkable evolution, particularly in the realm of oncology. In recent years, a significant portion of R&D investments has been channeled into cancer research, paving the way for groundbreaking treatments and therapies.
Genentech, a prominent subsidiary of Roche, is undergoing significant layoffs and restructuring efforts, which are slated to impact various roles at its South San Francisco operations. This development follows a recent announcement that 93 employees will be laid off starting in early October. The
Recent research breakthroughs have revealed an intriguing and unexpected benefit of certain cancer drugs: the potential to protect against Alzheimer's disease. Originally developed for combating cancer, these medications have shown promise in preventing Alzheimer's in animal models such as mice,
